NasdaqCM - Nasdaq Real Time Price USD
Akebia Therapeutics, Inc. (AKBA)
2.6250
+0.0150
+(0.57%)
As of 10:37:31 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 2 | 2 | 1 | 2 |
| Avg. Estimate | -0.04 | -0.05 | -0.09 | 0.12 |
| Low Estimate | -0.04 | -0.08 | -0.09 | -0.18 |
| High Estimate | -0.04 | -0.03 | -0.09 | 0.42 |
| Year Ago EPS | -0.04 | -0.1 | -0.33 | -0.09 |
Revenue Estimate
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| No. of Analysts | 5 | 5 | 4 | 5 |
| Avg. Estimate | 47.15M | 43.88M | 198.61M | 282.44M |
| Low Estimate | 45.8M | 38.7M | 184.4M | 209.4M |
| High Estimate | 50.8M | 48.89M | 206.14M | 395.54M |
| Year Ago Sales | 43.65M | 37.43M | 160.18M | 198.61M |
| Sales Growth (year/est) | 8.03% | 17.23% | 23.99% | 42.21% |
Earnings History
| Currency in USD | 6/30/2024 | 9/30/2024 | 12/31/2024 | 3/31/2025 |
|---|---|---|---|---|
| EPS Est. | -0.05 | -0.05 | -0.08 | -0.04 |
| EPS Actual | -0.04 | -0.1 | -0.1 | 0.02 |
| Difference | 0.01 | -0.05 | -0.03 | 0.06 |
| Surprise % | 20.00% | -100.00% | -33.33% | 161.75% |
EPS Trend
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Current Estimate | -0.04 | -0.05 | -0.09 | 0.12 |
| 7 Days Ago | -0.05 | -0.04 | -0.15 | 0.08 |
| 30 Days Ago | -0.05 | -0.04 | -0.15 | 0.08 |
| 60 Days Ago | -0.05 | -0.04 | -0.15 | 0.05 |
| 90 Days Ago | -0.05 | -0.02 | -0.14 | 0.1 |
EPS Revisions
| Currency in USD | Current Qtr. (Jun 2025) | Next Qtr. (Sep 2025) | Current Year (2025) | Next Year (2026) |
|---|---|---|---|---|
| Up Last 7 Days | -- | 1 | 1 | 1 |
| Up Last 30 Days | -- | -- | 1 | 1 |
| Down Last 7 Days | 1 | -- | -- | -- |
| Down Last 30 Days | 1 | 1 | 1 | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| AKBA | 0.00% | 45.00% | 72.42% | 233.33% |
| S&P 500 | 13.32% | 2.67% | 7.78% | 13.75% |
Upgrades & Downgrades
| Initiated | Leerink Partners: Outperform | 4/28/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/4/2025 |
| Initiated | Jefferies: Buy | 4/1/2025 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/14/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 3/14/2025 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 1/23/2025 |
Related Tickers
AQST Aquestive Therapeutics, Inc.
2.3550
-1.05%
BCRX BioCryst Pharmaceuticals, Inc.
10.24
0.00%
SCYX SCYNEXIS, Inc.
0.8301
+5.08%
ESPR Esperion Therapeutics, Inc.
0.8401
+4.78%
AVDL Avadel Pharmaceuticals plc
9.12
+1.22%
RMTI Rockwell Medical, Inc.
0.9979
-1.20%
ASRT Assertio Holdings, Inc.
0.6872
+3.20%
IRWD Ironwood Pharmaceuticals, Inc.
0.5766
+1.16%
DVAX Dynavax Technologies Corporation
9.70
+0.26%
ETON Eton Pharmaceuticals, Inc.
19.10
+0.90%